Announcement PDF NEUREN PHARMACEUTICALS LIMITED RESULT OF GENERAL MEETING (ASX REPORT) ANNUAL GENERAL MEETING Tuesday, 31 May, 2016 As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda. Manner in which the securityholder directed the proxy vote (as at proxy close): Resolution Manner in which votes were cast in person or by proxy on a poll (where applicable) Votes For Votes Against Votes Discretionary Votes Abstain For Against Abstain ** 1 RE-ELECT RICHARD TREAGUS AS A DIRECTOR OF THE COMPANY 337,284,416 17,912,602 10,827,785 1,350,001 Passed on a show of hands Passed on a show of hands Passed on a show of hands 2 APPROVAL IS GIVEN TO THE PRIOR ISSUE OF 70,555,555 SHARES AT AN ISSUE PRICE OF $0.09 PER SHARE ON 17 NOVEMBER 2015 345,412,258 2,872,909 4,062,576 31,000 Passed on a show of hands Passed on a show of hands Passed on a show of hands 3 RE-APPOINTMENT OF PRICEWATERHOUSECOOPERS AS THE AUDITOR 354,942,209 39,809 10,827,785 1,565,001 Passed on a show of hands Passed on a show of hands Passed on a show of hands 4 THAT THE COMPANYS CONSTITUTION BE AMENDED 353,611,557 1,659,812 11,708,185 395,250 Passed on a show of hands Passed on a show of hands Passed on a show of hands ** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item Printed: 31/05/2016 11:57:17AM This report was produced from the Link Market Services AGM System v2007 Page 1 of 1